RecruitingPhase 3NCT06003387
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Study DirectorCSL Behring
- Intervention
- CSL222 (AAV5-hFIXco-Padua)(genetic)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2032
Study locations (26)
- University of California, San Diego (UCSD), San Diego, California, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Royal Brisbane Hospital, Herston, Queensland, Australia
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- The Alfred Hospital, Melbourne, Victoria, Australia
- McMaster University - Hamilton, Hamilton, Ontario, Canada
- Queen Mary Hospital, Hong Kong, Hong Kong
- Prince of Wales Hospital Chinese University of Hong Kong, Shatin, Hong Kong
- Sheba Medical Center, Tel Litwinsky, Israel
- Centro de Investigacion Clinica GRAMEL S.C., Mexico City, Mexico City, Mexico
- King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- National University Hospital, Singapore, Singapore
- Singapore General Hospital, Singapore, Singapore
- Haemophilia Comprehensive Care Centre, Johannesburg, South Africa
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06003387 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE3NCT05662319A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaSanofi